Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb.
A retrospective study of 91 patients with malignant melanoma treated by lower limb isolated hyperthermic regional perfusion was performed. Objective response in patients with evaluable disease was 78 per cent. The role of perfusion as primary treatment of large melanomas of the foot is confirmed and recommended. Control of locoregional disease and limb salvage remains a valuable and attainable therapeutic goal using this technique.
Skene
A I
AI
Department of Academic Surgery, Royal Marsden Hospital, London, UK.
Bulman
A S
AS
Williams
T R
TR
Thomas
J M
JM
Westbury
G
G
D010478:Chemotherapy, Cancer, Regional Perfusion; D006801:Humans; D006979:Hyperthermia, Induced; D007866:Leg; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D012189:Retrospective Studies
D008558:Melphalan